Evidence map›Paper›PMID 22206029›Full record

ArticlePLoS neglected tropical diseases2011

Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protection.

Saumyabrata Mazumder, Mithun Maji, Nahid Ali

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
5.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Review
  3. Evaluation ofMicrobiology spectrum · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Pathogen Evasion of Chemokine Response Through Suppression of CXCL10.Frontiers in cellular and infection microbiology · 2019
    Article
  9. Article
  10. Liposomal adjuvant development for leishmaniasis vaccines.Therapeutic advances in vaccines · 2017
    Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. An overview on Leishmania vaccines: A narrative review article.Veterinary research forum : an international quarterly journal · 2015
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Saumyabrata MazumderInfectious Diseases and Immunology Division, Indian Institute of Chemical Biology, Jadavpur, Kolkata, India.
Mithun Maji
Nahid Ali
Indian Institute of Chemical Biology · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVaccines that activate strong specific Th1-predominant immune responses are critically needed for many intracellular pathogens, including Leishmania. The requirement for sustained and efficient vaccination against leishmaniasis is to formulate the best combination of immunopotentiating adjuvant with the stable antigen (Ag) delivery system. The aim of the present study is to evaluate the effectiveness of an immunomodulator on liposomal Ag through subcutaneous (s.c.) route of immunization, and its usefulness during prime/boost against visceral leishmaniasis (VL) in BALB/c mice. METHODOLOGY/PRINCIPAL

findingsTowards this goal, we formulated recombinant GP63 (rGP63)-based vaccines either with monophosphoryl lipid A-trehalose dicorynomycolate (MPL-TDM) or entrapped within cationic liposomes or both. Combinatorial administration of liposomes with MPL-TDM during prime confers activation of dendritic cells, and induces an early robust T cell response. To investigate whether the combined formulation is required for optimum immune response during boost as well, we chose to evaluate the vaccine efficacy in mice primed with combined adjuvant system followed by boosting with either rGP63 alone, in association with MPL-TDM, liposomes or both. We provide evidences that the presence of either liposomal rGP63 or combined formulations during boost is necessary for effective Th1 immune responses (IFN-γ, IL-12, NO) before challenge infection. However, boosting with MPL-TDM in conjugation with liposomal rGP63 resulted in a greater number of IFN-γ producing effector T cells, significantly higher levels of splenocyte proliferation, and Th1 responses compared to mice boosted with liposomal rGP63, after virulent Leishmania donovani (L. donovani) challenge. Moreover, combined formulations offered superior protection against intracellular amastigote replication in macrophages in vitro, and hepatic and splenic parasite load in vivo.

conclusionOur results define the immunopotentiating effect of MPL-TDM on protein Ag encapsulated in a controlled release system against experimental VL.

Indexed as

Adjuvants, ImmunologicAnimalsCord FactorsCytokinesDisease Models, AnimalFemaleHumansInjections, SubcutaneousLeishmania donovaniLeishmaniasis VaccinesLeishmaniasis, VisceralLipid ALiposomesMetalloendopeptidasesMiceMice, Inbred BALB C1,2-distearoyllecithin6,6'-dicorynomycolyl trehaloseAdjuvants, ImmunologicCord FactorsCytokinesglycoprotein gp63, LeishmaniaLeishmaniasis VaccinesLipid ALiposomesMetalloendopeptidasesmonophosphoryl lipid ANitric OxidePhosphatidylcholinesVaccines, Synthetic

Identifiers

PMID22206029
PMCPMC3243702
OpenAlexW2155764951

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.